Related Concept Videos
01:28Rabies
Rabies is a lethal zoonotic disease caused by a single-stranded, negative-sense RNA virus of the Lyssavirus genus, within the family Rhabdoviridae. Its primary mode of transmission to humans is through bites or saliva-contaminated scratches from infected mammals such as dogs, bats, raccoons, or foxes. Transmission can also occur if infectious saliva contacts abraded skin or intact mucous membranes, including the conjunctiva.Viral Entry and Early ReplicationOnce introduced at the bite or scratch...
00:42Cross-reactivity
Overview
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Polycystic ovary syndrome: associations with cardiovascular disease.
Climacteric : the journal of the International Menopause Society·2023
Same author
Hip arthroplasty practice across the Organisation for Economic Co-operation and Development (OECD) over the last decade.
Annals of the Royal College of Surgeons of England·2023
Same author
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
ESMO open·2022
Related Experiment Video
Updated: Jun 19, 2026
07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
Bee venom immunotherapy - how early is it effective?
1Allergy and Clinical Immunology Unit, Meir Hospital, Kfar-Saba, Israel.
Allergy
|October 21, 2009
Summary
Bee venom immunotherapy (VIT) is effective immediately after reaching the maintenance dose (MD). Most patients tolerate stings uneventfully, and increased doses provide protection for non-responders.
Area of Science:
- Immunology
- Allergy and Clinical Immunology
- Ophthalmology
Background:
- Venom immunotherapy (VIT) for bee venom (BV) allergy is established.
- Efficacy of VIT immediately after reaching the maintenance dose (MD) was previously unevaluated.
- This study assessed bee VIT effectiveness within one week of achieving the MD.
Purpose of the Study:
- To evaluate the immediate effectiveness of bee venom immunotherapy (VIT) after reaching the maintenance dose (MD).
- To determine if the MD provides adequate protection against bee stings shortly after administration.
Main Methods:
- Bee venom allergic patients received conventional or rush VIT.
- Patients were challenged with a live bee sting within one week of reaching the 100 microg MD.
Main Results:
- 73.8% of patients reaching MD were challenged.
- 88.6% tolerated the sting uneventfully; 5.1% had mild local reactions.
- 6.3% experienced mild-moderate systemic reactions, with increased MDs providing protection.
Conclusions:
- Bee VIT demonstrates effectiveness in most patients immediately post-MD.
- For a minority not protected by the initial MD, increased doses offer immediate protection.
- MD dosage, not accumulated dose or duration, is key for protection against re-stings.